Cargando…

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

PURPOSE: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothnie, Kieran J, Numbere, Beade, Gelwicks, Steven, Lu, Yifei, Sharma, Raj, Compton, Chris, Ismaila, Afisi S, Quint, Jennifer K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676117/ https://www.ncbi.nlm.nih.gov/pubmed/38022832 http://dx.doi.org/10.2147/COPD.S413947

Ejemplares similares

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records
por: Rothnie, Kieran J., et al.
Publicado: (2016)

Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records
por: Rothnie, Kieran J, et al.
Publicado: (2016)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records
por: Whittaker, Hannah, et al.
Publicado: (2023)

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
por: Sansbury, Leah B, et al.
Publicado: (2022)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care
por: Rothnie, Kieran J, et al.
Publicado: (2017)

COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
por: Hanania, Nicola A, et al.
Publicado: (2023)

SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study
por: Ismaila, AS, et al.
Publicado: (2022)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study
por: Whittaker, Hannah, et al.
Publicado: (2022)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
por: Halpin, David M G, et al.
Publicado: (2022)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis
por: Rothnie, Kieran J, et al.
Publicado: (2015)

SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study
por: Rothnie, KJ, et al.
Publicado: (2022)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
por: Whittaker, Hannah, et al.
Publicado: (2022)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
por: Iheanacho, Ike, et al.
Publicado: (2020)

Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data
por: Pinto, Paulo, et al.
Publicado: (2017)

Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes
por: Rothnie, Kieran J., et al.
Publicado: (2016)

Renaming COPD exacerbations: the UK respiratory nursing perspective
por: Mwasuku, Christine, et al.
Publicado: (2021)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

COPD management costs according to the frequency of COPD exacerbations in UK primary care
por: Punekar, Yogesh Suresh, et al.
Publicado: (2014)

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)

Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study
por: Whittaker, Hannah, et al.
Publicado: (2023)

Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review
por: Dang-Tan, Tam, et al.
Publicado: (2015)

Acute kidney injury in stable COPD and at exacerbation
por: Barakat, MF, et al.
Publicado: (2015)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

No association between exacerbation frequency and stroke in patients with COPD
por: Windsor, Claire, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0ciq97oiljtt88mf49otihov7v